SLC2A4 and Glucose intolerance: BA treatment ameliorates diabetes-mediated glucose intolerance by activation of GLUT4 expression, attenuates hyperglycemia-induced oxidative stress and inflammation by Nrf2 activation and NFκB p65 signaling suppression, and plays a vascular protective role by stimulation of eNOS expression.